• Je něco špatně v tomto záznamu ?

First Use of Open-Source Automated Insulin Delivery AndroidAPS in Full Closed-Loop Scenario: Pancreas4ALL Randomized Pilot Study

L. Petruzelkova, V. Neuman, L. Plachy, M. Kozak, B. Obermannova, S. Kolouskova, S. Pruhova, Z. Sumnik

. 2023 ; 25 (5) : 315-323. [pub] 20230313

Jazyk angličtina Země Spojené státy americké

Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011598

Objective: We evaluated the safety and feasibility of open-source automated insulin delivery AndroidAPS in adolescents and young adults with type 1 diabetes (T1D) and compared its efficacy in three different scenarios: hybrid closed loop (HCL) with meal boluses, meal announcement only (MA), and full closed loop (FCL). Research Design and Methods: In an open-label, prospective, randomized crossover trial (clinicaltrials.gov NCT04835350), 16 adolescents with T1D (10 females) with mean age of 17 years (range 15-20), glycated hemoglobin 56 mmol/mol (range 43-75), and mean duration of diabetes 5.9 years (9-15) underwent three distinct 3-day periods of camp living, comparing the above-mentioned scenarios of AndroidAPS. We used modified and locked version of AndroidAPS 3.1.03, which was called Pancreas4ALL for study purposes. The order of MA and FCL periods was assigned randomly. The primary endpoints were feasibility and safety of the system represented by percentage of time of glucose control by the system and time in hypoglycemia below 3 mmol/L. Results: The glycemia was controlled by the system 95% time of the study and the proportion of time below 3 mmol/L did not exceed 1% over the whole study period (0.72%). The HCL scenario reached significantly higher percentage of time below 3 mmol/L (HCL 1.05% vs. MA 0.0% vs. FCL 0.0%; P = 0.05) compared to other scenarios. No difference was observed among the scenarios in the percentage of time between 3.9 and 10 mmol/L (HCL 83.3% vs. MA 79.85% vs. FCL 81.03%, P = 0.58) corresponding to mean glycemia (HCL 6.65 mmol/L vs. MA 7.34 mmol/L vs. FCL 7.05 mmol/L, P = 0.28). No difference was observed in the mean daily dose of insulin or in the daily carbohydrate intake. No serious adverse event occurred during the study period. Conclusions: Our pilot study showed that FCL might be a realistic mode of treatment for people with T1D.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011598
003      
CZ-PrNML
005      
20230801133156.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1089/dia.2022.0562 $2 doi
035    __
$a (PubMed)36826996
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Petruzelkova, Lenka $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000255353474
245    10
$a First Use of Open-Source Automated Insulin Delivery AndroidAPS in Full Closed-Loop Scenario: Pancreas4ALL Randomized Pilot Study / $c L. Petruzelkova, V. Neuman, L. Plachy, M. Kozak, B. Obermannova, S. Kolouskova, S. Pruhova, Z. Sumnik
520    9_
$a Objective: We evaluated the safety and feasibility of open-source automated insulin delivery AndroidAPS in adolescents and young adults with type 1 diabetes (T1D) and compared its efficacy in three different scenarios: hybrid closed loop (HCL) with meal boluses, meal announcement only (MA), and full closed loop (FCL). Research Design and Methods: In an open-label, prospective, randomized crossover trial (clinicaltrials.gov NCT04835350), 16 adolescents with T1D (10 females) with mean age of 17 years (range 15-20), glycated hemoglobin 56 mmol/mol (range 43-75), and mean duration of diabetes 5.9 years (9-15) underwent three distinct 3-day periods of camp living, comparing the above-mentioned scenarios of AndroidAPS. We used modified and locked version of AndroidAPS 3.1.03, which was called Pancreas4ALL for study purposes. The order of MA and FCL periods was assigned randomly. The primary endpoints were feasibility and safety of the system represented by percentage of time of glucose control by the system and time in hypoglycemia below 3 mmol/L. Results: The glycemia was controlled by the system 95% time of the study and the proportion of time below 3 mmol/L did not exceed 1% over the whole study period (0.72%). The HCL scenario reached significantly higher percentage of time below 3 mmol/L (HCL 1.05% vs. MA 0.0% vs. FCL 0.0%; P = 0.05) compared to other scenarios. No difference was observed among the scenarios in the percentage of time between 3.9 and 10 mmol/L (HCL 83.3% vs. MA 79.85% vs. FCL 81.03%, P = 0.58) corresponding to mean glycemia (HCL 6.65 mmol/L vs. MA 7.34 mmol/L vs. FCL 7.05 mmol/L, P = 0.28). No difference was observed in the mean daily dose of insulin or in the daily carbohydrate intake. No serious adverse event occurred during the study period. Conclusions: Our pilot study showed that FCL might be a realistic mode of treatment for people with T1D.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mladiství $7 D000293
650    _2
$a mladý dospělý $7 D055815
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    12
$a inzulin $x terapeutické užití $7 D007328
650    12
$a diabetes mellitus 1. typu $x farmakoterapie $7 D003922
650    _2
$a hypoglykemika $7 D007004
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prospektivní studie $7 D011446
650    _2
$a inzulinové infuzní systémy $7 D007332
650    _2
$a inzulin lidský $x terapeutické užití $7 D061386
650    _2
$a klinické křížové studie $7 D018592
650    _2
$a krevní glukóza $7 D001786
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Neuman, Vit $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Plachy, Lukas $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kozak, Milos $u IT Department, CLOSED LOOP Systems and Sysop, Prague, Czech Republic
700    1_
$a Obermannova, Barbora $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kolouskova, Stanislava $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pruhova, Stepanka $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Sumnik, Zdenek $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00173679 $t Diabetes technology & therapeutics $x 1557-8593 $g Roč. 25, č. 5 (2023), s. 315-323
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36826996 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133153 $b ABA008
999    __
$a ok $b bmc $g 1963810 $s 1197863
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 25 $c 5 $d 315-323 $e 20230313 $i 1557-8593 $m Diabetes technology & therapeutics $n Diabetes Technol Ther $x MED00173679
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...